Developer docs
API playgroundTry for free, no card

Search company profiles

Corundum

Full company profile

uuid02mb2a9

Namestring
Corundum
Legal namestring
Corundum Corp.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Corundum Corp. is a Tokyo-headquartered international innovation group founded in 2014 by Yasushi Yamamoto, operating four hubs: Corundum Open Innovation (COI), a venture capital arm investing in Israeli and global science-and-technology startups via funds including COIF I and COIF II; Corundum Systems Biology (CSB), which invests in and sponsors research on human phenotyping, microbiome, and multi-omics; Corundum Neuroscience (CNS, formerly Joy Ventures), which backs neuroscience ventures; and Corundum Convergence Institute (CCI), a Delaware-registered 501(c)(3) non-profit sponsoring research in neuroscience, systems biology, and AI. The company explicitly connects Japanese corporate capital with Israeli and US life-sciences innovation, anchored by Japanese corporate LPs including Nikon Corporation and NGK Insulators in COIF II.

The group's investment portfolio includes Theranica (FDA-cleared Nerivio migraine wearable, $45M Series C), GrayMatters Health (FDA 510(k)-cleared Prism for PTSD digital therapy), Concerto Biosciences ($23M Series A), Freya Biosciences ($38M Series A), and Sequential ($3.5M, March 2026). Eleven direct/indirect portfolio companies from COIF I have completed exits through M&A and IPO, providing a track record supporting successor-fund formation. Corundum also maintains scientific partnerships with MIT, Harvard T.H. Chan School of Public Health, the Weizmann Institute of Science, OIST, and St. Marianna University School of Medicine, and advises through senior scientific leadership including Prof. Eran Segal and Prof. Takao Hensch.

Revenue is generated through three principal streams: venture capital fund management and carry from portfolio exits (COIF I and COIF II), professional consulting services for Japanese corporations seeking Israeli innovation exposure (using non-public information from fund activities), and sponsored research and venture philanthropy through CCI. Pricing is quote-based for institutional investors and corporate clients and is not publicly disclosed. The firm operates from Tokyo (HQ), Boston (adjacent to MIT), Herzliya, and Luxembourg.

Short descriptiontext

Corundum Corp. is a Tokyo-headquartered international innovation group that operates four hubs (venture capital, systems biology, neuroscience, and a non-profit research institute) connecting Japanese corporate capital with Israeli and US life-sciences startups, while sponsoring research in microbiome, neuroscience, and AI.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investment, open innovation consulting, scientific research sponsorship, microbiome research investment, neuroscience venture funding
Industry2 codes
PRIMARYFSAHAKAJ
Co-Investment Aggregators & Multi-Manager Co-Invest Vehicles
Financial & Insurance/Hedge Funds & Alternative Investments/Alternative Investments — Fund of Funds & Multi-Manager Platforms
SECONDARYFSANAHAC
Corporate Venture Studios & Incubators (Build/launch ventures)
SIC code2 codes
  • Investment Advice6282
  • Services-Management Consulting Services8742
Product category
Venture Capital and Innovation Investment
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Venture Capital Investment Returns
TypeTransaction Fee
Description

Corundum generates returns through equity investments in Israeli high-tech startups and top VC funds via funds such as COIF-I and COIF-II. The company earns financial returns through exits via M&A and IPO from its portfolio companies.

corundum-corp.com
2Consulting Services for New Business Development
TypeProfessional Services
Description

Corundum provides consulting services to fund investors for new business development, utilizing non-public information from fund activities. Services include strategic planning, startup search, partnership negotiation, and direct investment support.

corundum-corp.com
3Sponsored Research and Venture Philanthropy
TypeLicensing Royalties
Description

Through Corundum Convergence Institute (CCI), a 501(c)(3) non-profit, the company sponsors research in neuroscience, systems biology, and AI. Through Corundum Systems Biology and Corundum Neuroscience, the company provides sponsored research funding.

corundum-corp.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Corundum is an international innovation group that operates venture capital funds (COIF-I and COIF-II) investing in Israeli high-tech and life-science startups, provides consulting services to Japanese corporations seeking to invest in innovative startups, and sponsors scientific research in neuroscience, systems biology, and AI through its group entities including the 501(c)(3) Corundum Convergence Institute.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 11 direct/indirect portfolio startups completed exits through M&A and IPO from COIF I
+1 more record
Product overview1 text field

Corundum Corp. is an international innovation group focused on convergence, bringing together Researchers, Investors, and Innovators to create synergies between Science, Technology, and Business. The group operates through four innovation hubs: Corundum Open Innovation (COI) provides venture capital and consulting services for AI and life sciences; Corundum Systems Biology (CSB) invests in human phenotyping and microbiome research; Corundum Neuroscience (CNS) advances neuroscience research and companies; and Corundum Convergence Institute (CCI) serves as a 501(c)(3) non-profit foundation sponsoring research in neuroscience, systems biology, and AI. The company also maintains a portfolio of invested companies including Sequential, GrayMatters Health, Theranica, Concerto Biosciences, and Freya Biosciences.

Product and service1 record
1Corundum Open Innovation (COI)
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1St. Marianna University School of Medicine
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-08-06
Description

Collaboration with St. Marianna University School of Medicine for the Human Phenotype Project, supporting diverse recruitment for one of the world's deepest human health datasets.

corundum-corp.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-18
Description

Prof. Eran Segal from Weizmann Institute serves on Corundum Systems Biology's Advisory Board. His lab focuses on Microbiome, Nutrition, Genetics, and personalized medicine research.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-11-15
Description

Collaboration between Corundum Systems Biology and Corundum Neuroscience to advance research and investment activities in gut-brain axis, including collaboration with Harvard-affiliated researchers.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-09-14
Description

Corundum organizes Converge events at OIST, bringing together innovators. The 2025 event featured highlights from the convergence conference.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-04-21
Description

Corundum Systems Biology became the main sponsor of the Harvard Chan Microbiome in Public Health Center's 'Microbial Communities Beyond the Bacteriome' Symposium in May 2023.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-12-09
Description

Joy Ventures (now Corundum Neuroscience) co-sponsored the 'Augmenting Brains 2022' symposium with MIT, focusing on augmenting brain functions. Collaboration with MIT Professor Pattie Maes and Professor Rosalind Picard.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pitango is an established Israel-focused venture capital investor spanning technology and life sciences. Its fund-based startup investment model is closely comparable to Corundum Open Innovation, although Pitango does not focus specifically on the Japan-Israel corporate bridge.

2JVP Media Labs
TypeDirect peer
Description

JVP is a long-standing Israeli venture capital firm that builds and invests in technology companies. It is a close category peer in Israeli startup sourcing and fund deployment, but has a more concentrated sector mandate than Corundum.

TypeDirect peer
Description

Global Brain is a Japan-based venture capital and open-innovation investor connecting startups with corporations. Its combination of global startup investing and corporate innovation services closely overlaps Corundum's COI proposition.

TypeDirect peer
Description

SOSV is a global multi-stage venture firm operating thematic programs and accelerator-driven investments in deep technology and life sciences. Its multi-program platform and hands-on venture model are comparable to Corundum's specialized innovation hubs.

TypeDirect peer
Description

OurCrowd operates a global venture investment platform focused heavily on Israeli technology companies and funds. It is comparable through its startup and fund investment activity, although its online investment distribution model differs from Corundum's enterprise-led model.

TypeDirect peer
Description

500 Global is a global venture platform that invests through funds, accelerators, and direct company transactions. It is comparable to Corundum in deploying capital across technology startup ecosystems, though at substantially greater scale and breadth.

TypeBroad incumbent
Description

Flagship Pioneering creates and funds companies in biotechnology and other scientific fields through an integrated venture-building model. It is comparable to Corundum's venture-building and sponsored-research orientation, but operates at a much larger scale and focuses primarily on company formation.

TypeBroad incumbent
Description

M Ventures is the corporate venture arm of Merck KGaA and invests globally in life-science and technology businesses. Its strategic venture model and life-sciences orientation overlap with Corundum's corporate-investor and neuroscience activities, but it is backed by a single global industrial company.

9Real Tech Fund
TypeDirect peer
Description

Real Tech Fund is a Japan-based deep-technology venture capital firm supporting science- and engineering-intensive startups. It is closely comparable to Corundum's focus on deep science, although it has a more exclusively Japanese investment mandate.

TypeBroad incumbent
Description

JAFCO is a Japanese venture capital and investment company with a broad technology and growth-company portfolio. It is a relevant incumbent comparator for Corundum's Japanese fund-management operations, but is considerably larger and more diversified.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Corundum

Venture Capital and Innovation Investmentcorundum-corp.com

Corundum Corp. is a Tokyo-headquartered international innovation group that operates four hubs (venture capital, systems biology, neuroscience, and a non-profit research institute) connecting Japanese corporate capital with Israeli and US life-sciences startups, while sponsoring research in microbiome, neuroscience, and AI.

What Corundum does

Corundum Corp. is a Tokyo-headquartered international innovation group founded in 2014 by Yasushi Yamamoto, operating four hubs: Corundum Open Innovation (COI), a venture capital arm investing in Israeli and global science-and-technology startups via funds including COIF I and COIF II; Corundum Systems Biology (CSB), which invests in and sponsors research on human phenotyping, microbiome, and multi-omics; Corundum Neuroscience (CNS, formerly Joy Ventures), which backs neuroscience ventures; and Corundum Convergence Institute (CCI), a Delaware-registered 501(c)(3) non-profit sponsoring research in neuroscience, systems biology, and AI. The company explicitly connects Japanese corporate capital with Israeli and US life-sciences innovation, anchored by Japanese corporate LPs including Nikon Corporation and NGK Insulators in COIF II.

The group's investment portfolio includes Theranica (FDA-cleared Nerivio migraine wearable, $45M Series C), GrayMatters Health (FDA 510(k)-cleared Prism for PTSD digital therapy), Concerto Biosciences ($23M Series A), Freya Biosciences ($38M Series A), and Sequential ($3.5M, March 2026). Eleven direct/indirect portfolio companies from COIF I have completed exits through M&A and IPO, providing a track record supporting successor-fund formation. Corundum also maintains scientific partnerships with MIT, Harvard T.H. Chan School of Public Health, the Weizmann Institute of Science, OIST, and St. Marianna University School of Medicine, and advises through senior scientific leadership including Prof. Eran Segal and Prof. Takao Hensch.

Revenue is generated through three principal streams: venture capital fund management and carry from portfolio exits (COIF I and COIF II), professional consulting services for Japanese corporations seeking Israeli innovation exposure (using non-public information from fund activities), and sponsored research and venture philanthropy through CCI. Pricing is quote-based for institutional investors and corporate clients and is not publicly disclosed. The firm operates from Tokyo (HQ), Boston (adjacent to MIT), Herzliya, and Luxembourg.

Corundum firmographics

Firmographics
Name
Corundum
Legal name
Corundum Corp.
Website
https://corundum-corp.com
Company type
Private
Founded year
2014
Operating status
Operating
Short description
Corundum Corp. is a Tokyo-headquartered international innovation group that operates four hubs (venture capital, systems biology, neuroscience, and a non-profit research institute) connecting Japanese corporate capital with Israeli and US life-sciences startups, while sponsoring research in microbiome, neuroscience, and AI.
Ownership category
akta.pro rank

Corundum industry classification

Industry
Product category
Venture Capital and Innovation Investment
SIC
Investment Advice (6282), Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYFSAHAKAJ
Co-Investment Aggregators & Multi-Manager Co-Invest Vehicles
Financial & Insurance/Hedge Funds & Alternative Investments/Alternative Investments — Fund of Funds & Multi-Manager Platforms
SECONDARYFSANAHAC
Corporate Venture Studios & Incubators (Build/launch ventures)

Keywords

  • Venture capital investment
  • Open innovation consulting
  • Scientific research sponsorship
  • Microbiome research investment
  • Neuroscience venture funding

Where Corundum is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices5 records

Markets served

Corundum business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Venture Capital Investment Returns: Corundum generates returns through equity investments in Israeli high-tech startups and top VC funds via funds such as COIF-I and COIF-II. The company earns financial returns through exits via M&A and IPO from its portfolio companies.
  2. Consulting Services for New Business Development: Corundum provides consulting services to fund investors for new business development, utilizing non-public information from fund activities. Services include strategic planning, startup search, partnership negotiation, and direct investment support.
  3. Sponsored Research and Venture Philanthropy: Through Corundum Convergence Institute (CCI), a 501(c)(3) non-profit, the company sponsors research in neuroscience, systems biology, and AI. Through Corundum Systems Biology and Corundum Neuroscience, the company provides sponsored research funding.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Corundum product offering

Product offering

Core offering

Corundum is an international innovation group that operates venture capital funds (COIF-I and COIF-II) investing in Israeli high-tech and life-science startups, provides consulting services to Japanese corporations seeking to invest in innovative startups, and sponsors scientific research in neuroscience, systems biology, and AI through its group entities including the 501(c)(3) Corundum Convergence Institute.

Product overview

Corundum Corp. is an international innovation group focused on convergence, bringing together Researchers, Investors, and Innovators to create synergies between Science, Technology, and Business. The group operates through four innovation hubs: Corundum Open Innovation (COI) provides venture capital and consulting services for AI and life sciences; Corundum Systems Biology (CSB) invests in human phenotyping and microbiome research; Corundum Neuroscience (CNS) advances neuroscience research and companies; and Corundum Convergence Institute (CCI) serves as a 501(c)(3) non-profit foundation sponsoring research in neuroscience, systems biology, and AI. The company also maintains a portfolio of invested companies including Sequential, GrayMatters Health, Theranica, Concerto Biosciences, and Freya Biosciences.

Differentiator

Problem solved

Functional benefit

Products and services

  • Corundum Open Innovation (COI)

Quantifiable outcome

  • 11 direct/indirect portfolio startups completed exits through M&A and IPO from COIF I
  • +1 more outcomes

Companies that use Corundum

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Corundum technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Corundum partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered major and core.

  • St. Marianna University School of MedicinemajorStrategic or Co-development Partner · 6 August 2024Collaboration with St. Marianna University School of Medicine for the Human Phenotype Project, supporting diverse recruitment for one of the world's deepest human health datasets.
  • Weizmann Institute of SciencecoreStrategic or Co-development Partner · 18 March 2024Prof. Eran Segal from Weizmann Institute serves on Corundum Systems Biology's Advisory Board. His lab focuses on Microbiome, Nutrition, Genetics, and personalized medicine research.
  • Harvard UniversitymajorStrategic or Co-development Partner · 15 November 2023Collaboration between Corundum Systems Biology and Corundum Neuroscience to advance research and investment activities in gut-brain axis, including collaboration with Harvard-affiliated researchers.
  • OIST (Okinawa Institute of Science and Technology)majorStrategic or Co-development Partner · 14 September 2023Corundum organizes Converge events at OIST, bringing together innovators. The 2025 event featured highlights from the convergence conference.
  • Harvard T.H. Chan School of Public HealthmajorStrategic or Co-development Partner · 21 April 2023Corundum Systems Biology became the main sponsor of the Harvard Chan Microbiome in Public Health Center's 'Microbial Communities Beyond the Bacteriome' Symposium in May 2023.
  • MIT Media LabmajorStrategic or Co-development Partner · 9 December 2022Joy Ventures (now Corundum Neuroscience) co-sponsored the 'Augmenting Brains 2022' symposium with MIT, focusing on augmenting brain functions. Collaboration with MIT Professor Pattie Maes and Professor Rosalind Picard.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Corundum competitors and assessment

Company assessment

Direct peers

  • Pitango Venture Capital: Pitango is an established Israel-focused venture capital investor spanning technology and life sciences. Its fund-based startup investment model is closely comparable to Corundum Open Innovation, although Pitango does not focus specifically on the Japan-Israel corporate bridge.
  • JVP Media Labs: JVP is a long-standing Israeli venture capital firm that builds and invests in technology companies. It is a close category peer in Israeli startup sourcing and fund deployment, but has a more concentrated sector mandate than Corundum.
  • Global Brain Corporation: Global Brain is a Japan-based venture capital and open-innovation investor connecting startups with corporations. Its combination of global startup investing and corporate innovation services closely overlaps Corundum's COI proposition.
  • SOSV: SOSV is a global multi-stage venture firm operating thematic programs and accelerator-driven investments in deep technology and life sciences. Its multi-program platform and hands-on venture model are comparable to Corundum's specialized innovation hubs.
  • OurCrowd: OurCrowd operates a global venture investment platform focused heavily on Israeli technology companies and funds. It is comparable through its startup and fund investment activity, although its online investment distribution model differs from Corundum's enterprise-led model.
  • 500 Global: 500 Global is a global venture platform that invests through funds, accelerators, and direct company transactions. It is comparable to Corundum in deploying capital across technology startup ecosystems, though at substantially greater scale and breadth.
  • Real Tech Fund: Real Tech Fund is a Japan-based deep-technology venture capital firm supporting science- and engineering-intensive startups. It is closely comparable to Corundum's focus on deep science, although it has a more exclusively Japanese investment mandate.

Broad incumbents

  • Flagship Pioneering: Flagship Pioneering creates and funds companies in biotechnology and other scientific fields through an integrated venture-building model. It is comparable to Corundum's venture-building and sponsored-research orientation, but operates at a much larger scale and focuses primarily on company formation.
  • M Ventures: M Ventures is the corporate venture arm of Merck KGaA and invests globally in life-science and technology businesses. Its strategic venture model and life-sciences orientation overlap with Corundum's corporate-investor and neuroscience activities, but it is backed by a single global industrial company.
  • JAFCO Group: JAFCO is a Japanese venture capital and investment company with a broad technology and growth-company portfolio. It is a relevant incumbent comparator for Corundum's Japanese fund-management operations, but is considerably larger and more diversified.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Corundum social profiles

Digital presence

Corundum financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Corundum leadership team

Management profile

Number of profiles

Profiles12 records

Corundum subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Corundum funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Corundum M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corundum

What does Corundum do?

Corundum is an international innovation group that operates venture capital funds (COIF-I and COIF-II) investing in Israeli high-tech and life-science startups, provides consulting services to Japanese corporations seeking to invest in innovative startups, and sponsors scientific research in neuroscience, systems biology, and AI through its group entities including the 501(c)(3) Corundum Convergence Institute.

Is Corundum a public or private company?

Corundum is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Corundum founded?

Corundum was founded in 2014.

Where is Corundum based?

Corundum is headquartered in Tokyo, Japan, in the Asia region.

How does Corundum make money?

Three revenue lines are on record. Venture Capital Investment Returns are the primary driver. The others are consulting Services for New Business Development and sponsored Research and Venture Philanthropy.

Who are Corundum's main competitors?

Direct peers on record are Pitango Venture Capital, JVP Media Labs, Global Brain Corporation, SOSV, OurCrowd, 500 Global and Real Tech Fund. Broad incumbents are Flagship Pioneering, M Ventures and JAFCO Group.

Does Corundum have an API?

No public API is recorded for Corundum.

What industry is Corundum in?

Corundum's product category is Venture Capital and Innovation Investment. Its primary akta.pro industry code is FSAHAKAJ, Co-Investment Aggregators & Multi-Manager Co-Invest Vehicles, with a secondary code of FSANAHAC, Corporate Venture Studios & Incubators (Build/launch ventures). Its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales